Drugs / Chimeric receptor T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06027983 | Nov → Dec 2026 expected | HER2 positive breast carcinoma | National University Hospital, Singapore | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chimeric receptor T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06027983 ↗ |
| Modality | Cell therapy | “autologous chimeric receptor T-cells” NCT06027983 ↗ |